bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies

bluebird bio, Inc. announced that the FDA has lifted the clinical holds on the Phase I/II HGB-206 and Phase III HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 and Northstar-3 studies of betibeglogene autotemcel gene therapy for adult, adolescent and pediatric patients with transfusion-dependent β-thalassemia.
[bluebird bio, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share
Share